BMS' Opdivo+Yervoy combo fails in small cell lung cancer

Bristol-Myers Squibb has revealed that its combo comprising Opdivo (nivolumab) and Yervoy (ipilimumab) failed to meet its primary endpoint as a maintenance treatment for extensive-stage small cell lung cancer (SCLC) without disease progression following the completion of first-line platinum-based chemotherapy.

Compared to placebo, the manufacturer said that its PD-1 inhibitor/CTLA-4 inhibitor combo failed to improve the Phase 3 trial’s primary endpoint of overall survival compared to placebo. It is not known whether the therapy managed to meet its secondary endpoint of overall survival improvement for Opdivo as a monotherapy.

News of the failure send shares falling by 4%. BMS said that it would be working with investigators on the study to ensure the publication of full results from the study.

-----------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.